Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.
Timmermand OV, Elgqvist J, Beattie KA, Örbom A, Larsson E, Eriksson SE, Thorek DLJ, Beattie BJ, Tran TA, Ulmert D, Strand SE.
Timmermand OV, et al. Among authors: orbom a.
Theranostics. 2019 Apr 6;9(8):2129-2142. doi: 10.7150/thno.31179. eCollection 2019.
Theranostics. 2019.
PMID: 31149033
Free PMC article.